24 completed, 11 unknown, 6 recruiting, 3 terminated. 22 Phase 2, 9 Not applicable, 7 Phase 3, 3 Phase 1, 3 Phase 4.
Follow Diabetic Peripheral Neuropathic Pain: new trials by email Literature Review of Diabetic Peripheral Neuropathic Pain trials Research Report on Diabetic Peripheral Neuropathic Pain
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of HRS-2129 in Patients With Diabetic Peripheral Neuropathic Pain HRS-2129 Tablets, HRS-2129 Placebo, Pregabalin Capsules - Diabetic Peripheral Neuropathic Pain | Phase 1 | Recruiting | Shandong Suncadia Medicine Co., Ltd. | 168 | 2026-03-24 | 2026-04-15 |
| A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain LY4065967, Placebo - Diabetic Peripheral Neuropathic Pain | Phase 2 | Recruiting | Eli Lilly and Company | 150 | 2026-02-16 | 2026-07-07 |
| Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy Suzetrigine, Placebo (matched to SUZ) - Diabetic Peripheral Neuropathic Pain | Phase 3 | Recruiting | Vertex Pharmaceuticals Incorporated | 734 | 2025-11-21 | 2026-07-20 |
| Evaluate the Efficacy and Safety of HL-1186 in Patients With Diabetic Peripheral Neuropathic Pain HL-1186, HL-1186 placebo - Diabetic Peripheral Neuropathic Pain | Phase 2 | Not yet recruiting | Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. | 180 | 2025-09-01 | 2025-09-08 |
| A Study to Evaluate the Safety and Effectiveness of Mirogabalin in Chinese Adult Patients With Diabetic Peripheral Neuropathic Pain (DPNP) in Real-world Clinical Practice Setting (ReMIssion Study) No Drug - Diabetic Peripheral Neuropathic Pain | Completed | Daiichi Sankyo | 721 | 2025-01-24 | 2026-10-14 | |
| Buerger Exercises With Whole Body Vibration in Diabetic Peripheral Neuropathy Group A, Group B - Diabetic Peripheral Neuropathic Pain, Balance Changes | Not applicable | Completed | Riphah International University | 64 | 2024-12-20 | 2025-08-22 |
| Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN) Suzetrigine - Diabetic Peripheral Neuropathic Pain | Phase 3 | Active not recruiting | Vertex Pharmaceuticals Incorporated | 455 | 2024-12-18 | 2026-10-30 |
| A Study of Medical Cannabis Aerosol Via the Fixed-dose Syqe Inhaler as an Add-on Treatment of Diabetic Peripheral Neuropathic Pain (DPNP) Medical Cannabis, Placebo - Diabetic Peripheral Neuropathic Pain | Phase 2 | Completed | Syqe Medical | 122 | 2024-11-14 | 2026-06-29 |
| Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy VX-993, Pregabalin, Placebo (matched to pregabalin) - Diabetic Peripheral Neuropathic Pain | Phase 2 | Recruiting | Vertex Pharmaceuticals Incorporated | 300 | 2024-10-18 | 2026-06-01 |
| Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy Suzetrigine, Placebo (matched to SUZ), Pregabalin - Diabetic Peripheral Neuropathic Pain | Phase 3 | Recruiting | Vertex Pharmaceuticals Incorporated | 1100 | 2024-10-01 | 2026-10-15 |
| Real-World Pharmacological Treatment Pattern of Neuropathic Pain in China No Drug - Diabetic Peripheral Neuropathic Pain, Chemotherapy-induced Peripheral Neuropathy | Completed | Daiichi Sankyo | 1271 | 2024-08-16 | 2025-07-23 | |
| MAD Study to Assess the Safety, Tolerability, PKs and Efficacy of YJ001 for Spray Use in Patients With DPNP YJ001 for Spray Use, Placebo of YJ001 for Spray Use - Diabetic Peripheral Neuropathic Pain | Phase 1 | Recruiting | Zhejiang Hanmai Pharmaceutical Technology Co., Ltd. | 24 | 2024-05-16 | 2025-08-13 |
| Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Diabetic Peripheral Neuropathic Pain Who Had an Inadequate Response to Pregabalin HSK16149 20mg BID, Pregabalin 150mg BID - Diabetic Peripheral Neuropathic Pain | Phase 2 | Unknown | Haisco Pharmaceutical Group Co., Ltd. | 90 | 2024-04-19 | 2024-07-08 |
| Evaluate the Efficacy and Safety of JMKX000623 in Participants With Diabetic Peripheral Neuropathic Pain JMKX000623, Pregabalin, Placebo - Diabetic Peripheral Neuropathic Pain | Phase 2 | Unknown | Jemincare | 220 | 2024-03-25 | 2024-04-16 |
| A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP) Placebo (blinded), LX9211 (blinded) - Diabetic Peripheral Neuropathic Pain | Phase 2 | Completed | Lexicon Pharmaceuticals | 496 | 2023-11-29 | 2025-10-10 |
| Effectiveness of Electroacupuncture in the Treatment of Diabetic Peripheral Neuropathy Basal therapy+EA, Basal therapy - Diabetic Peripheral Neuropathic Pain | Not applicable | Unknown | Zhejiang Chinese Medical University | 104 | 2023-10-01 | 2023-09-26 |
| A Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain RTA 901, RTA 901-Matching Placebo - Diabetic Peripheral Neuropathic Pain | Phase 2 | Terminated | Reata, a wholly owned subsidiary of Biogen | 209 | 2023-07-28 | 2025-12-15 |
| Diabetic Neuropathic Pain Relief, 6 Weeks Dosage Sublingual Water-soluble CBD/PEA CBD/PEA, Placebo - Diabetic Peripheral Neuropathic Pain | Phase 1 / Phase 2 | Unknown | Pure Green Pharmaceuticals Inc. | 52 | 2023-06-05 | 2023-03-13 |
| To Evaluate the Efficacy and Safety of HSK16149 With L-carnitine in Diabetic Peripheral Neuralgia Patients in China HSK16149 20mg BID - Diabetic Peripheral Neuropathic Pain | Not applicable | Unknown | Haisco Pharmaceutical Group Co., Ltd. | 136 | 2023-05-01 | 2023-11-08 |
| A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05). LY3857210, Placebo - Diabetic Peripheral Neuropathic Pain | Phase 2 | Completed | Eli Lilly and Company | 131 | 2022-11-14 | 2024-08-07 |
Showing 20 of 48. Sign in to see all of them.
Diabetes Mellitus (6) · Pain (4) · Neuralgia (3) · Diabetic Neuropathies (2) · Bronchiolitis Obliterans Syndrome (1) · Cognitive Dysfunction (1) · Depressive Disorder, Major (1) · Diabetic Foot (1) · Fibromyalgia (1) · Generalized Anxiety Disorder (1) · Marijuana Abuse (1) · Neuralgia, Postherpetic (1) · Renal Insufficiency (1) · Respiratory Aspiration (1)
Endocrine System Diseases (8) · Pathological Conditions, Signs and Symptoms (8) · Nervous System Diseases (7) · Neurologic Manifestations (7) · Neuromuscular Diseases (7) · Signs and Symptoms (7) · Glucose Metabolism Disorders (6) · Metabolic Diseases (6) · Nutritional and Metabolic Diseases (6) · Peripheral Nervous System Diseases (6) · Diabetes Complications (3) · Mental Disorders (3) · Pain (3) · Diabetes Mellitus (2) · Respiratory Tract Diseases (2)
Pregabalin (11) · BID protein, human (3) · Duloxetine Hydrochloride (3) · mirogabalin (3) · Cognitive Behavioral Therapy (1) · Electroacupuncture (1) · Medical Marijuana (1) · Muscle Stretching Exercises (1) · NYX-2925 (1) · Neuropsychological Tests (1) · Patient Education as Topic (1) · Ranolazine (1) · Sugars (1) · Thioctic Acid (1) · Transcranial Magnetic Stimulation (1)
Eli Lilly and Company (7) · Vertex Pharmaceuticals Incorporated (4) · Daiichi Sankyo Co., Ltd. (3) · Haisco Pharmaceutical Group Co., Ltd. (3) · Daiichi Sankyo (2) · Riphah International University (2) · Aga Khan University (1) · Algiamed Technologies USA, Inc. (1) · Aptinyx (1) · Bristol-Myers Squibb (1) · Eliem Therapeutics (UK) Ltd. (1) · Forest Laboratories (1) · Horizons International Peripheral Group (1) · Instituto Mexicano del Seguro Social (1) · Jemincare (1)
United States (22) · China (10) · Puerto Rico (5) · Australia (2) · Canada (2) · Czechia (2) · France (2) · Germany (2) · Israel (2) · Japan (2) · Mexico (2) · Pakistan (2) · United Kingdom (2) · Hong Kong (1) · Italy (1)
Allyson Gage, PhD (1) · Aruba Saeed, PhD (1) · Christine Sang (1) · Craig M Walker, MD FACC (1) · Debra Kimless, M.D. (1) · Debra Kimless, MD (1) · Douglas Scott Denham (1)
PMID 20932222, PMID 26885528, PMID 30271191, PMID 32765056, PMID 34059327, PMID 35322973, PMID 38896199, PMID 39158916, PMID 39193463, PMID 40266472, PMID 40377855, PMID 40788612, PMID 41366387, PMID 41384808, PMID 41849003, PMID 42039234, PMID 42249666
2023 (1)